A recent analytical study by seven Moroccan researchers has shown Morocco’s progress in controlling the spread of hepatitis B virus (HBV) between 2000 and 2024. 

Published in BMC Infectious Diseases, the study suggests that the country has moved toward a low-prevalence status for the disease, with rates comparable to those observed in countries with low HBV incidence, rather than in nations with medium or high prevalence.

The researchers attribute these results to the effectiveness of Morocco’s multi-faceted approach, which combined technical, financial, political, educational, and regulatory measures, alongside the national vaccination program launched in 1999. 

The study also points to the need for continued efforts to maintain this progress and address weaknesses in national disease management.

The team reviewed data from multiple scientific databases, including PubMed, Google Scholar, Web of Science, and Scopus. Their analysis showed limited scientific output on HBV in Morocco during the first eight years of the 2000s, with only three studies identified. 

Research activity increased significantly between 2009 and 2016, with approximately 13 studies conducted, averaging 1.3 per year and peaking at five in a single year.